1. |
How best to prevent ischaemic stroke? |
|
Inpharma Weekly,
Volume &NA;,
Issue 1268,
2000,
Page 2-2
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2000
数据来源: ADIS
|
2. |
News in brief ... |
|
Inpharma Weekly,
Volume &NA;,
Issue 1268,
2000,
Page 3-3
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2000
数据来源: ADIS
|
3. |
Nisoldipine better value for money for treating hypertension |
|
Inpharma Weekly,
Volume &NA;,
Issue 1268,
2000,
Page 4-4
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2000
数据来源: ADIS
|
4. |
Esomeprazole's superiority more than just a gut feeling |
|
Inpharma Weekly,
Volume &NA;,
Issue 1268,
2000,
Page 5-6
Amanda Cameron,
Preview
|
|
摘要:
Esomeprazole, the first proton pump inhibitor to be developed as an optical isomer, is quickly proving its worth. This innovative agent has been shown to be more successful than omeprazole in healing reflux oesophagitis, irrespective of the severity of the disease. It has also been shown to be effective for long-term on-demand treatment to control recurrent symptoms in patients with gastro-oesophageal reflux disease (GORD). Now, research spearheaded by Dr P Wahlqvist from AstraZeneca R&D Mölndal, Sweden, indicates that esomeprazole is cost effective compared with omeprazole, with the potential to generate substantial cost savings for health systems in Europe.
ISSN:1173-8324
出版商:ADIS
年代:2000
数据来源: ADIS
|
5. |
Triple therapy: valuable new era in treating HIV/AIDS |
|
Inpharma Weekly,
Volume &NA;,
Issue 1268,
2000,
Page 7-7
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2000
数据来源: ADIS
|
6. |
RAD plus MMF: superior corneal graft rejection prophylaxis? |
|
Inpharma Weekly,
Volume &NA;,
Issue 1268,
2000,
Page 8-8
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2000
数据来源: ADIS
|
7. |
News from ASH ... |
|
Inpharma Weekly,
Volume &NA;,
Issue 1268,
2000,
Page 9-9
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2000
数据来源: ADIS
|
8. |
News in brief ... |
|
Inpharma Weekly,
Volume &NA;,
Issue 1268,
2000,
Page 10-10
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2000
数据来源: ADIS
|
9. |
Spotlight on pioglitazone in type 2 diabetes |
|
Inpharma Weekly,
Volume &NA;,
Issue 1268,
2000,
Page 11-12
Carmen Innes,
Preview
|
|
摘要:
The place of pioglitazone in type 2 diabetes mellitus has recently been confirmed by data released at the 17th Congress of the International Diabetes Federation [Mexico City, Mexico; November 2000]. The studies show that pioglitazone in combination with a sulfonylurea, metformin or insulin significantly improves glycaemic control, compared with standard antihyperglycaemic monotherapy. Furthermore, glycaemic control achieved with pioglitazone monotherapy is sustainable for up to 2.5 years. Thus, pioglitazone has the potential to become a useful addition to the armamentarium of agents used for the management of type 2 diabetes.
ISSN:1173-8324
出版商:ADIS
年代:2000
数据来源: ADIS
|
10. |
News in brief ... |
|
Inpharma Weekly,
Volume &NA;,
Issue 1268,
2000,
Page 12-12
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2000
数据来源: ADIS
|